Develops, manufactures, and sells medicines for diabetes, cancer, and other conditions to wholesalers and healthcare providers.
10-K for FY2025, filed Feb 12, 2026Eli Lilly and Company (referred to as the company, Lilly, we, or us) was incorporated in 1901 in Indiana to succeed to the drug…View ↗
MounjaroView ↗
Oncology productsView ↗
Immunology productsView ↗
In the U.S., most of our products are distributed through wholesalers that serve pharmacies, physicians and other healthcare professionals…View ↗
Lilly sells medicines to customers, who pay after products ship. It also receives collaboration profit shares, royalties tied to partners' product sales, upfront and milestone payments, and proceeds from selling product rights.
10-K for FY2025, filed Feb 12, 2026Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance…View ↗
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations…View ↗
Royalty revenue from licensees and certain of our collaboration partners, which is based on sales to third parties of licensed products and…View ↗
The net gain or loss related to the sale of rights of a product is included in collaboration and other revenue when control of the asset…View ↗
10-K for FY2025, filed Feb 12, 2026
FY2025 revenue by product or service ↗$65.2B
10-K for FY2025, filed Feb 12, 2026
$65.2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenue
Sold outright
10-K for FY2025, filed Feb 12, 2026 |
94%
FY2022: 89%
|
Net product revenue, FY2025
$61B Sources
|
Sold outright |
|
Collaboration and Other Revenue
Mix
|
6.5%
FY2022: 11%
|
Collaboration and Other Revenue, FY2025
$4.2B Sources
|
Mix |
Most medicines go through wholesalers serving pharmacies, healthcare professionals, and hospitals; Lilly also works with insurers and health-plan organizations on access and rebates. In some jurisdictions, LillyDirect offers patients delivery of select medicines dispensed by third-party pharmacies.
10-K for FY2025, filed Feb 12, 2026In the U.S., most of our products are distributed through wholesalers that serve pharmacies, physicians and other healthcare professionals…View ↗
Our account managers service wholesalers, pharmacy benefit managers, insurers, plan sponsors, employers, managed care organizations, group…View ↗
In certain jurisdictions, we utilize LillyDirect, our direct-to-patient digital health care platform, to provide delivery of select Lilly…View ↗
Yes. It kept 32 cents of every revenue dollar as net income in FY2025 and turned 14 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Aug 5, 2026
Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94…View ↗
Growing. Revenue grew 2.3x in 4 years, from $28.3B in FY2021 to $65.2B in FY2025, about 23% a year.
Obesity treatment
The older report lists Mounjaro as a diabetes treatment; the latest report also lists Zepbound for obesity and overweight, adding a named use for tirzepatide.
10-K for FY2022, filed Feb 22, 2023Basaglar®, in collaboration with Boehringer Ingelheim, a long-acting human insulin analog for the treatment of diabetes. Humalog®, Humalog…View ↗
Loading...